PAD Medical Therapy
Definition
Guideline-directed medical therapy (GDMT) for peripheral artery disease (PAD) encompasses antithrombotic therapy, lipid-lowering therapy, antihypertensive therapy, smoking cessation, diabetes management, and claudication-specific drugs. The 2024 ACC/AHA PAD guidelines provide comprehensive evidence-graded recommendations for each component; GDMT is the foundation of PAD management across all severity categories.
Key Concepts
Antithrombotic Therapy
- Single antiplatelet therapy (aspirin 75–325 mg/day OR clopidogrel 75 mg/day): COR 1 for symptomatic PAD. Clopidogrel showed improved efficacy vs aspirin in CAPRIE with similar bleeding risk. (sources/PVD-AHA-2024 — very high)
- Rivaroxaban 2.5 mg BID + aspirin 81 mg/day: COR 1A for symptomatic PAD (COMPASS trial) and post-revascularisation PAD (VOYAGER PAD trial) — reduces MACE and major adverse limb events (MALE). Contraindicated at high bleeding risk or prior stroke/intracranial haemorrhage. (sources/PVD-AHA-2024)
- Full-intensity oral anticoagulation (without a separate indication): COR 3:Harm — WAVE trial: no MACE/MALE benefit with increased bleeding. (sources/PVD-AHA-2024)
- Post-endovascular revascularisation DAPT (P2Y12 + aspirin): COR 2a for at least 1–6 months. (sources/PVD-AHA-2024)
Lipid-Lowering Therapy
- High-intensity statin: COR 1A — reduces MALE by 30%, amputation by 35%, all-cause death by 39% (meta-analysis n=138,060). Targets ≥50% LDL-C reduction (atorvastatin 40–80 mg or rosuvastatin 20–40 mg). (sources/PVD-AHA-2024 — very high)
- PCSK9 inhibitor (if LDL-C ≥70 mg/dL on maximal statin): COR 2a — evolocumab HR 0.63 for MALE (FOURIER); alirocumab HR 0.59 for MALE (ODYSSEY). (sources/PVD-AHA-2024)
- Ezetimibe (if LDL-C ≥70 mg/dL on maximal statin): COR 2a. (sources/PVD-AHA-2024)
Antihypertensive Therapy
- Target SBP <130/80 mmHg: COR 1A. ACEi or ARB preferred first-line for PAD + hypertension (HOPE trial: ramipril reduced MI/stroke/vascular death by 25% in PAD subgroup). Beta-blockers do not worsen claudication; no adverse MALE signal. (sources/PVD-AHA-2024)
Smoking Cessation
- COR 1A at every visit. Pharmacotherapy (varenicline, bupropion, nicotine replacement therapy) + counselling increases cessation rate 2–3× over self-quit. 5-year mortality 40–50% with active smoking + chronic symptomatic PAD; PAD risk remains elevated >2× for up to 10–20 years after cessation. (sources/PVD-AHA-2024 — very high)
Diabetes Management
- GLP-1 agonists (liraglutide, semaglutide) and SGLT-2 inhibitors: COR 1A for T2DM + PAD — reduce MACE. Glycaemic control (HbA1c) is associated with MALE reduction (COR 2b, observational evidence only). (sources/PVD-AHA-2024)
- Canagliflozin lower-extremity amputation concern (CANVAS trial) was not reproduced in CREDENCE or subsequent meta-analysis; FDA black-box warning removed August 2020. (sources/PVD-AHA-2024)
Claudication-Specific Pharmacotherapy
- Cilostazol (PDE-III inhibitor): COR 1A for claudication symptom improvement and walking distance. Absolutely contraindicated in heart failure of any severity (COR 3:Harm) — Class effect PDE-III inhibition increases mortality in HF. COR 2b for restenosis reduction after femoropopliteal endovascular therapy. (sources/PVD-AHA-2024)
- Pentoxifylline: COR 3:No Benefit for claudication. (sources/PVD-AHA-2024)
Other Preventive Measures
- Annual influenza vaccination: COR 1; SARS-CoV-2 vaccination: COR 1.
- Mediterranean diet: COR 2a for MACE reduction in high-risk patients.
- B-complex vitamins, chelation therapy, vitamin D: COR 3:No Benefit for MACE prevention. (sources/PVD-AHA-2024)
Contradictions / Open Questions
- COMPASS vs VOYAGER PAD population: COMPASS enrolled stable PAD patients; VOYAGER PAD enrolled post-revascularisation patients. Whether the COMPASS benefit applies robustly to post-revascularisation patients (who already qualify for VOYAGER PAD) — and vice versa — requires clinical judgement given differing baseline risks. (sources/PVD-AHA-2024)
- Canagliflozin amputation signal: Despite FDA warning removal, individual clinicians remain cautious about canagliflozin in severe PAD patients. Absolute risk is low and probably trial-specific, but the biological mechanism (volume depletion worsening limb perfusion in critical ischaemia) is plausible. (sources/PVD-AHA-2024)
Connections
- Related to concepts/PAD-Exercise-Therapy
- Related to concepts/CLTI
- Related to concepts/Ankle-Brachial-Index
- Related to entities/Peripheral-Artery-Disease
- Related to entities/COMPASS-Trial
- Related to entities/VOYAGER-PAD-Trial